Alas, Moderna's recent performance is really underwhelming... Closed at $24.06, down 0.41%. The peak rally is over, and the stock price has halved from its all-time high. The vaccine business is dragged down by cyclical factors, overseas expansion lacks catalysts, and community engagement is plummeting 🕳️. The turnover rate looks decent, but ETF tracking and foreign capital allocation are mediocre—everyone prefers to wait and see. Recent news flow is thin, the company has barely any buyback activity, and dividends are out of the question... The whole sector is sluggish...